ISOkine® Premium · IK0500
VEGF 165 (human)
Recombinant VEGF 165 (human) for angiogenesis, endothelial proliferation. Animal-free and endotoxin-free, produced in barley with >95% purity and <0.01 EU/µg endotoxin, and batch-to-batch consistency you can validate once and scale.
Datasheets, SDS, and Certificate of Origin available for download or on request.
About VEGF 165 (human)
VEGF 165 (Vascular endothelial growth factor) is the only growth factor that stimulates vascular permeability. It promotes endothelial proliferation and survival, angiogenesis, vasculognesis and inhibits apoptosis. VEGF 165 mitogenic activity is specific for endothelial cell and that makes it distinct among other growth factors. VEGF 165 is thought to be important in the pathophysiology of neuronal and other tumors, by functioning as a prompter of angiogenesis for human gliomas. Human VEGF occurs in several molecular variants and the 165 form is the most common form in most tissues. Biological activities of VEGF 165 are not species specific and glycosylation is not required for biological activity.
Biological activity
The bioactivity of ISOkine® recombinant human VEGF 165 was assayed by measuring its dose dependent effect on proliferation of Human Umbilical Vein Endothelial Cells (HUVEC).
The ED50 for this effect is < 10 ng/ml corresponding to specific activity of > 1 x 10e5 U/mg. Optimal concentration should be determined for specific applications and cell lines.
We recommend that the optimal concentration for each specific application be determined by an initial dose-response assay. Each batch of this ISOkine® growth factors is tested for bioactivity and verified to have comparable activity to a commercial source.
VEGF 165 (human) bioactivity: dose-dependent response assay.
At a glance
Specifications
Starting price for research quantities. Volume pricing on request.
Purity verified by SDS-PAGE gel analysis on every lot.
Produced in an endotoxin-free barley host, tested per batch.
Datasheet specifications
| Property | Detail |
|---|---|
| Source | Produced in the endosperm tissue of barley grain (Hordeum vulgare). |
| Molecular Weight | Recombinant human VEGF 165 contains 165 amino acids and a 16 a.a. Histidine based tag for a total length of 181 a. a. and has a predicted molecular mass of 21.3 kDa. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 26-28 kDa in SDS PAGE. |
| Purity | Greater than 95% by SDS-PAGE gel analysis. |
| Endotoxin Level | Endotoxin level is < 0.01 EU per μg of ISOkine® product (< 0.01 EU/μg). |
| Pyrogen Free | Purified ISOkine® product carries no pyrogenic or pro-inflammatory contaminants, as assayed with monocyte activation (MAT Assay) test using Human 10-plex Cytokine Assay measuring IL-6, TNF-alpha and IL-1beta induction. |
| Storage | The lyophilized protein, though stable at room temperature for few weeks, is best stored at -20°C. Reconstituted protein should be used immediately or stored in working aliquots at -20°C. Avoid repeated freeze-thaw cycles. |
| Stability | Highly stable as supplied for a maximum of 5 years and a minimum of 12 months from date of receipt (check expiration date specific for each lot# on Certificate of Analysis) |
| Reconstitution | Note: Always centrifuge the vial before opening. It is recommended to reconstitute the lyophilized protein in sterile buffered saline to a concentration of no less than 100 µg/ml. For long term storage of the reconstituted solution it is recommended to add a carrier protein (0.1% HSA or BSA). |
| Formulation | PBS pH 7.2, sterile filtered through 0.2 µm filter. |
Size and pricing
| Pack size | List price (EUR) |
|---|---|
| 10 µg | €125 |
| 5 × 10 µg | €350 |
| 50 µg | €325 |
| 10 × 10 µg | €525 |
| 100 µg | €500 |
| 5 × 100 µg | €1650 |
| 10 × 100 µg | €2750 |
| 1000 µg | €2500 |
| 20 × 100 µg | €4900 |
| 2 × 1000 µg | €4850 |
| 2000 µg | €4750 |
| 50 × 100 µg | €9900 |
| 5 × 1000 µg | €9500 |
| 5000 µg | €8990 |
| Bulk (> 5 mg) | Please inquire |